News Headlines

  1. Kaigene Enters Into Exclusive Licensing Agreement With Taisho Pharmaceutical For Next-Generation Autoimmune Asset KG006 In Japan 7/30/2026

    Kaigene, Inc., a U.S.-based biotechnology company pioneering next-generation antibody therapeutics for autoimmune disorders, announced today that it has entered into an exclusive licensing agreement with Taisho Pharmaceutical Co., Ltd. ("Taisho"), a leading Japanese pharmaceutical company, for the exclusive development and commercialization of Kaigene's next-generation human neonatal Fc receptor (hFcRn) inhibitor, KG006, in Japan.

  2. EVERSANA Selected By Innovacell As Commercialization Partner To Advance Novel Cell Therapy ICEF15 In The United States 7/30/2026

    EVERSANA®, a leading provider of global commercialization services to the life sciences industry, today announced it has been selected by Tokyo-based biotechnology company Innovacell Inc. as its exclusive commercialization partner in the United States.

  3. IMPACT Therapeutics Signs Exclusive License Agreement With Pharmanovia For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand 7/30/2026

    IMPACT Therapeutics (“IMPACT“) today is pleased to announce that it has entered into an exclusive partnership (the “Exclusive Partnership”) with Pharmanovia, a global specialty pharmaceutical company which partners with innovative biotech and large pharma to bring innovative specialty medicines to patients, to grant Pharmanovia the exclusive rights to manufacture, develop and commercialise senaparib in Europe, Middle East and North Africa, Australia and New Zealand for maintenance monotherapy for advanced epithelial high-grade ovarian, fallopian tube and primary peritoneal cancer.

  4. miRecule Announces Strategic Collaboration With EMS Group Company Rio Biopharma To Advance Targeted Delivery Of RNA Therapeutics 7/30/2026

    miRecule, Inc., a biotechnology company developing next-generation RNA therapeutics for rare genetic diseases, today announced a strategic research collaboration with Rio Biofarma Brasil Ltda. (RBBL), part of EMS S.A., Brazil’s largest pharmaceutical company.

  5. NurExone Launches Bioprocess Optimization Initiative To Support Commercial And Clinical Readiness 7/30/2026

    NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, today announced a bioprocess optimization initiative intended to support the manufacturing infrastructure for its therapeutic pipeline and commercial exosome activities.

  6. Resilience And Lilly Invest $750M To Increase U.S.-Manufactured Medicine Supply 7/30/2026

    Resilience, a technology-forward contract development and manufacturing organization dedicated to broadening access to complex medicines, today announced it has expanded its strategic partnership with Eli Lilly and Company to increase U.S. production of critical medicines featuring new pharmaceutical manufacturing investments in Ohio.

  7. Brenntag Pharma Announces Strategic Partnership With Budenheim For Biopharma Phosphates 7/29/2026

    Brenntag, the global market leader in chemicals and ingredients distribution, today announced a strategic partnership with Budenheim, a leading manufacturer of high-purity phosphate specialties, on biopharma phosphate solutions through complementary commercial models.

  8. Landmark Bio And Syngoi Technologies To Operate As Artis BioSolutions, An End-To-End Gene-To-GMP Platform For Genetic Medicines 7/29/2026

    Artis BioSolutions, an advanced therapies company built to streamline the discovery, development, and production of genetic medicines, today announced that both Landmark Bio, its Watertown, Massachusetts-based development and GMP manufacturing operation, and Syngoi, its Bilbao, Spain-based enzymatic synthetic DNA business, will now operate under the Artis BioSolutions name. 

  9. AbCellera Announces Collaboration With Vertex To Discover Multispecific T-Cell Engagers For Autoimmune Diseases And Other Conditions 7/29/2026

    AbCellera today announced a collaboration with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions.

  10. Sail Biomedicines Announces Strategic Collaboration To Develop New Class Of Medicines For In Vivo CAR-T 7/29/2026

    Sail Biomedicines, a Flagship Pioneering company creating a new class of RNA medicines, today announced a strategic collaboration with Johnson & Johnson to advance innovative In Vivo Chimeric Antigen Receptor T-cell (CAR-T) therapies that have the potential to improve patient outcomes for immune-mediated diseases.